1,544,607 Shares in X4 Pharmaceuticals, Inc. $XFOR Acquired by Rosalind Advisors Inc.

Rosalind Advisors Inc. acquired a new stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) during the 3rd quarter, HoldingsChannel reports. The firm acquired 1,544,607 shares of the company’s stock, valued at approximately $5,283,000. X4 Pharmaceuticals accounts for about 1.9% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 19th largest holding. Rosalind Advisors Inc. owned about 0.14% of X4 Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in X4 Pharmaceuticals by 77.0% in the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after buying an additional 178,593 shares during the last quarter. Jane Street Group LLC lifted its position in shares of X4 Pharmaceuticals by 112.5% during the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after buying an additional 51,544 shares during the last quarter. Bank of America Corp DE lifted its position in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after buying an additional 22,485 shares during the last quarter. Rhumbline Advisers grew its stake in shares of X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares during the period. Finally, Palumbo Wealth Management LLC bought a new position in shares of X4 Pharmaceuticals during the 3rd quarter worth $326,000. 72.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on XFOR. Zacks Research lowered X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Stifel Nicolaus set a $10.00 target price on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Finally, Guggenheim started coverage on X4 Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $12.00 price target for the company. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $28.88.

X4 Pharmaceuticals Stock Down 10.4%

Shares of NASDAQ:XFOR opened at $3.88 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. The firm has a market capitalization of $339.27 million, a PE ratio of -0.38 and a beta of 0.43. The firm has a fifty day moving average of $3.66 and a 200 day moving average of $3.63. X4 Pharmaceuticals, Inc. has a 52-week low of $1.35 and a 52-week high of $10.49.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.